Scribd Logo
Upload

Welcome to Scribd!

  • 10 views

    Zoledronic Acid Is Superior To Pamidronate in The Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials - PubMed

    Uploaded by

    Mike
    Two randomized controlled trials compared zoledronic acid and pamidronate for treating hypercalcemia of malignancy. Zoledronic acid achieved higher complete response rates than pamidronate by day 10. Patients treated with zoledronic acid also saw normalization of calcium levels faster than those receiving pamidronate. The median duration of complete response was longer for both doses of zoledronic acid compared to pamidronate. Based on these results, the study concluded zoledronic acid is superior to pamidronate for treating hypercalcemia of malignancy.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Zoledronic Acid Is Superior To Pamidronate in The Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials - PubMed

    Uploaded by

    Mike
    10 views2 pages
    Two randomized controlled trials compared zoledronic acid and pamidronate for treating hypercalcemia of malignancy. Zoledronic acid achieved higher complete response rates than pamidronate by day 10. Patients treated with zoledronic acid also saw normalization of calcium levels faster than those receiving pamidronate. The median duration of complete response was longer for both doses of zoledronic acid compared to pamidronate. Based on these results, the study concluded zoledronic acid is superior to pamidronate for treating hypercalcemia of malignancy.

    Original Title

    Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials - PubMed

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Two randomized controlled trials compared zoledronic acid and pamidronate for treating hypercalcemia of malignancy. Zoledronic acid achieved higher complete response rates than pamidronate by day 10. Patients treated with zoledronic acid also saw normalization of calcium levels faster than those receiving pamidronate. The median duration of complete response was longer for both doses of zoledronic acid compared to pamidronate. Based on these results, the study concluded zoledronic acid is superior to pamidronate for treating hypercalcemia of malignancy.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    10 views2 pages

    Zoledronic Acid Is Superior To Pamidronate in The Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials - PubMed

    Uploaded by

    Mike
    Two randomized controlled trials compared zoledronic acid and pamidronate for treating hypercalcemia of malignancy. Zoledronic acid achieved higher complete response rates than pamidronate by day 10. Patients treated with zoledronic acid also saw normalization of calcium levels faster than those receiving pamidronate. The median duration of complete response was longer for both doses of zoledronic acid compared to pamidronate. Based on these results, the study concluded zoledronic acid is superior to pamidronate for treating hypercalcemia of malignancy.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 2

    Zoledronic acid is superior to pamidronate in the treatment of hypercal… pooled analysis of two randomized, controlled clinical trials - PubMed

    22/10/23, 0:21

    An official website of the United States government


    Here's how you know

    FULL TXT LINKS

    Meta-Analysis J Clin Oncol. 2001 Jan 15;19(2):558-67. doi: 10.1200/JCO.2001.19.2.558.

    Zoledronic acid is superior to pamidronate in the


    treatment of hypercalcemia of malignancy: a pooled
    analysis of two randomized, controlled clinical trials
    P Major 1 , A Lortholary, J Hon, E Abdi, G Mills, H D Menssen, F Yunus, R Bell, J Body,
    E Quebe-Fehling, J Seaman

    Affiliations
    PMID: 11208851 DOI: 10.1200/JCO.2001.19.2.558

    Abstract
    Purpose: Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-
    dummy trials were conducted to compare the efficacy and safety of zoledronic acid and
    pamidronate for treating hypercalcemia of malignancy (HCM).

    Patients and methods: Patients with moderate to severe HCM (corrected serum calcium [CSC] >
    or = 3.00 mmol/L [12.0 mg/dL]) were treated with a single dose of zoledronic acid (4 or 8 mg) via 5-
    minute infusion or pamidronate (90 mg) via 2-hour infusion. A protocol-specified pooled analysis of
    the two parallel trials was performed. Clinical end points included rate of complete response by day
    10, response duration, and time to relapse.

    Results: Two hundred eighty-seven patients were randomized and evaluated for safety; 275 were
    evaluated for efficacy. Both doses of zoledronic acid were superior to pamidronate in the treatment
    of HCM. The complete response rates by day 10 were 88.4% (P = .002), 86.7% (P = .015), and
    69.7% for zoledronic acid 4 mg and 8 mg and pamidronate 90 mg, respectively. Normalization of
    CSC occurred by day 4 in approximately 50% of patients treated with zoledronic acid and in only
    33.3% of the pamidronate-treated patients. The median duration of complete response favored
    zoledronic acid 4 and 8 mg over pamidronate 90 mg with response durations of 32, 43, and 18
    days, respectively.

    Conclusion: Zoledronic acid is superior to pamidronate; 4 mg is the dose recommended for initial
    treatment of HCM and 8 mg for relapsed or refractory hypercalcemia.

    PubMed Disclaimer

    Related information
    Cited in Books
    MedGen
    PubChem Compound
    PubChem Compound (MeSH Keyword)

    https://pubmed.ncbi.nlm.nih.gov/11208851/ Página 1 de 2
    Zoledronic acid is superior to pamidronate in the treatment of hypercal… pooled analysis of two randomized, controlled clinical trials - PubMed 22/10/23, 0:21

    PubChem Substance

    LinkOut - more resources


    Full Text Sources
    Atypon
    Ovid Technologies, Inc.
    Other Literature Sources
    The Lens - Patent Citations

    https://pubmed.ncbi.nlm.nih.gov/11208851/ Página 2 de 2

    You might also like